ProPhase Labs Introduces Genetic Testing Subsidiary with Cuttingedge Technology

Published: 27 Nov 2024

Author: Precedence Research

Share :

ProPhase Labs has launched DNA Complete, a subsidiary offering direct-to-consumer genetic testing with virtually full genome sequencing. Providing much more than just health, wellness, and ancestry information, this provides the necessary height needed to launch ProPhase into a leadership role in this newly burgeoning marketplace of genetic testing. DNA Complete offers whole genome sequencing and thus delivers rich data to consumers on health-as-wellness and ancestry. It combines cutting-edge bioinformatics with advanced ancestry platforms to deliver the entire immersion experience at very affordable prices.

And, with this feature of sequencing, DNA Complete also provides genetic counselling services to interpret their results for users on how to best use the derived information. A subscription service to ensure that customers always have the latest reports keeps them updated by giving subscribers access to new reports. Flexible sample processing will be available to users through Nebula Genomics or any of the other leading genetics labs, guaranteeing high-quality results and fast turnaround time.

Alongside such sequencing, DNA Expand is a new offering from ProPhase; it is a subscription-based platform that will enable users of other ancestry tests to upload their DNA data and gain access to about 50 times more than that typically available through ordinary ancestry services. Importantly, no more sequencing is required for this feature, allowing access to significant insight at a very minimal cost. At $49.95 a year, these subscriptions provide strong profit margins due to very low production costs.

In addition, ProPhase Labs has invested a lot in a sophisticated campaign steered by Stu Hollenshead, a proven leader in the field of consumer engagement. The advancement that DNA Complete and DNA Expand bring to the direct-to-consumer genetic testing sphere is much to setting the standard amongst innovative affordability and accessibility. Health well-being, after all, is about transformation.

Direct-To-Consumer Laboratory Testing Market Size and Forecast 2024 to 2034

The global direct-to-consumer laboratory testing market size accounted for USD 3.44 billion in 2024 and is anticipated to reach around USD 8.07 billion by 2034, growing at a CAGR of 8.90% from 2024 to 2034.

Direct-to-Consumer Laboratory Testing Market Companies

• 23andMe, Inc
• Ambry Genetics Corp.
• Ancestry.com LLC
• Any Lab Test Now, Inc.
• Color Genomics, Inc
• Counsyl, Inc.
• DanteLabs Inc.
• Direct Laboratory Services, LLC
• Eastern Biotech & Life Sciences
• EasyDNA
• EverlyWell, Inc., 
• Full Genomes Corporation, Inc.
• Gene by Gene, Ltd.
• Genecodebook Oy

Direct-To-Consumer Laboratory Testing Recent Developments

• In October 2024, Luminate Health, a leading healthcare technology provider, successfully adopted its Direct-to-Consumer (DTC) lab testing platform, enabling laboratories to engage with patient communities, and making critical lab testing more accessible.
• In October 2024, Root Functional Medicine just launched a direct-access membership for lab testing and functional medicine expertise called "Root Access" after a $4-million seed round from the 4100 Group.
• In September 2024, Labcorp finalizes the acquisition of BioReference Health, a subsidiary under OPKO Health, thus further expanding its laboratory services horizons and offering advanced testing capabilities across important regions.
• In August 2024, Quest Diagnostics launched 13 blood tests for discovering micronutrient insufficiencies so that people can find their required vitamins and minerals for good health.

We’ve prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344